Autoclavable suspensions of cyclosporin a form 2

Abstract

Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.

What is claimed is: 
     
         1 . A formulation comprising cyclosporin A form 2 and a vehicle selected from carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hyaluronic acid, polyvinylpyrrolidone, Carbopol Ultrez 10NF, and Pluronic F127. 
     
     
         2 . The formulation of  claim 2 , wherein the cyclosporin A form 2 is at a concentration of about 0.01% to about 10%. 
     
     
         3 . A method of making a formulation of cyclosporin A, the method comprising the steps of
 a) dissolving cyclosporin A form 2 in solution;   b) autoclaving the solution;   c) adding a vehicle selected from carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hyaluronic acid, polyvinylpyrrolidone, Carbopol Ultrez 10NF, and Pluronic F127.   
     
     
         4 . A method of making a formulation of cyclosporin A, the method comprising the steps of
 a) dissolving in solution a vehicle selected from carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hyaluronic acid, polyvinylpyrrolidone, Carbopol Ultrez 10NF, and Pluronic F127;   b) adding to the solution cyclosporin A Form 2;   c) autoclaving the resulting mixture.   
     
     
         5 . A method of treating a condition selected from dry eye, blepharitis, meibomian gland disease, impaired corneal sensitivity, allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and ptyregia, the method comprising the step of administering to a patient having such a condition the formulation of  claim 3 . 
     
     
         6 . A method of treating a condition selected from dry eye, blepharitis, meibomian gland disease, impaired corneal sensitivity, allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and ptyregia, the method comprising the step of administering to a patient having such a condition the formulation of  claim 4 .